We envision the NSD2 function to evolve from enabling oncogenic AR activity in primary AR-dependent PCa to additionally supporting NSD1 in counter-balancing the canonical repressive PRC2 activity in the metastatic castration-resistant disease. The gene discussed is NSD1; the disease is posterior cortical atrophy.